Heat, oxygen, UV light, and contamination accelerate peptide degradation, which can reduce potency even if the peptide still looks unchanged
This active ingredient is in several well-known medications ( Ozempic , Wegovy , and Rybelsus ), each designed for different therapeutic purposes
The mechanisms behind GLP-1-related headaches are not fully understood, but likely involve changes in blood sugar levels (especially during early treatment when insulin sensitivity improves rapidly), dehydration from reduced fluid intake or GI losses, and the central nervous system effects of GLP-1 receptor activation, since GLP-1 receptors exist in the brain
Whilst the US Food and Drug Administration (FDA) has approved five drug therapies to treat obesity (orlistat, phentermine/topiramate, lorcaserin, naltrexone/bupropion, liraglutide), the European Medicines Agency (EMA) has approved only three drug therapies (orlistat, bupropion/naltrexone and liraglutide) [8] at the time of writing
M.GrayV.FarquharsonF
